Literature DB >> 7730842

Responsiveness and calibration of the General Well-Being Adjustment Scale in patients with hypertension.

D A Revicki1, H Allen, K Bungay, G H Williams, M C Weinstein.   

Abstract

We examined the discriminant ability and responsiveness of the General Well-Being Adjustment Scale in patients enrolled in a randomized clinical trial of antihypertensive therapy. We also tried to translate the effects of physical symptoms on general well-being. This secondary analysis used demographic, clinical, physical symptom, and general well-being data for 545 white, male hypertensive patients. General well-being was measured by the General Well-Being Adjustment Scale (GWB) collected on 2 occasions over 8 weeks of treatment. Patients with any one of 14 physical symptoms or problems, compared to those without symptoms, had lower GWB scores (p < 0.003 to p < 0.0001). Decreases of 2.83-8.76 points in GWB scores were observed in patients developing physical symptoms over the 8 week study period (p < 0.05 to p < 0.0001). These effects were demonstrated in patients developing cold sensitivity, sexual problems, chest pain, shortness of breath, loss of taste, nausea, hot or cold spells, numbness and tingling, dry mouth, blurred vision, and dizziness. We conclude that the GWB is responsive to clinically meaningful changes in symptoms and may provide a more complete evaluation of the effects of medical treatment. The GWB is a valid and responsive measure of health status outcomes in the evaluation of antihypertensive treatment.

Entities:  

Mesh:

Year:  1994        PMID: 7730842     DOI: 10.1016/0895-4356(94)90077-9

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  8 in total

Review 1.  Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

Authors:  G Samsa; D Edelman; M L Rothman; G R Williams; J Lipscomb; D Matchar
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

2.  Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.

Authors:  D A Revicki; M Wood; I Wiklund; J Crawley
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

Review 3.  Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life.

Authors:  D A Revicki; R M Kaplan
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

Review 4.  Psychometric considerations in evaluating health-related quality of life measures.

Authors:  R D Hays; R Anderson; D Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

Review 5.  Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures.

Authors:  Nicholas J Talley; Ingela Wiklund
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

6.  Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.

Authors:  Wei Jiang; Eric J Velazquez; Zainab Samad; Maragatha Kuchibhatla; Carolyn Martsberger; Joseph Rogers; Redford Williams; Cynthia Kuhn; Thomas L Ortel; Richard C Becker; Nicole Pristera; Ranga Krishnan; Christopher M O'Connor
Journal:  Am Heart J       Date:  2011-11-14       Impact factor: 4.749

7.  Evaluating the psychometric characteristics of the Psychological General Well-Being Index with a new response scale.

Authors:  D A Revicki; N K Leidy; L Howland
Journal:  Qual Life Res       Date:  1996-08       Impact factor: 4.147

8.  Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity.

Authors:  Dennis A Revicki; Marc W Zodet; Sandra Joshua-Gotlib; Douglas Levine; Joseph A Crawley
Journal:  Health Qual Life Outcomes       Date:  2003-11-29       Impact factor: 3.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.